Amundi Invests $374,000 in Medifast, Inc. (NYSE:MED)

Amundi acquired a new position in Medifast, Inc. (NYSE:MEDFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 21,215 shares of the specialty retailer’s stock, valued at approximately $374,000. Amundi owned approximately 0.19% of Medifast as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Exchange Traded Concepts LLC increased its holdings in shares of Medifast by 4.1% in the fourth quarter. Exchange Traded Concepts LLC now owns 17,106 shares of the specialty retailer’s stock valued at $301,000 after purchasing an additional 674 shares during the last quarter. Centiva Capital LP raised its holdings in Medifast by 6.3% in the 3rd quarter. Centiva Capital LP now owns 15,238 shares of the specialty retailer’s stock valued at $292,000 after buying an additional 898 shares during the last quarter. Quarry LP lifted its position in shares of Medifast by 148.6% in the 3rd quarter. Quarry LP now owns 6,629 shares of the specialty retailer’s stock worth $127,000 after purchasing an additional 3,962 shares during the period. Inspire Investing LLC increased its stake in shares of Medifast by 11.1% in the 4th quarter. Inspire Investing LLC now owns 54,270 shares of the specialty retailer’s stock valued at $956,000 after acquiring an additional 5,403 shares in the last quarter. Finally, Public Employees Retirement System of Ohio increased its stake in shares of Medifast by 1,161.8% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 9,766 shares of the specialty retailer’s stock valued at $187,000 after acquiring an additional 8,992 shares in the last quarter. Institutional investors own 95.51% of the company’s stock.

Medifast Stock Performance

Shares of NYSE:MED opened at $14.39 on Friday. The company’s 50-day moving average is $15.04 and its 200 day moving average is $17.27. The company has a market capitalization of $157.34 million, a P/E ratio of 79.92 and a beta of 1.13. Medifast, Inc. has a fifty-two week low of $13.57 and a fifty-two week high of $39.14.

Medifast (NYSE:MEDGet Free Report) last released its quarterly earnings data on Tuesday, February 18th. The specialty retailer reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.16) by $0.26. Medifast had a net margin of 0.35% and a return on equity of 10.64%. The business had revenue of $119.00 million for the quarter, compared to the consensus estimate of $114.25 million. As a group, research analysts predict that Medifast, Inc. will post 0.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, DA Davidson cut their price objective on shares of Medifast from $17.00 to $16.50 and set a “neutral” rating on the stock in a report on Wednesday, February 19th.

Check Out Our Latest Research Report on MED

About Medifast

(Free Report)

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.

Further Reading

Want to see what other hedge funds are holding MED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medifast, Inc. (NYSE:MEDFree Report).

Institutional Ownership by Quarter for Medifast (NYSE:MED)

Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.